Lambert-Eaton Myasthenic Syndrome (LES)

Firdapse ®  (currently approved in the EU) is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults, a rare autoimmune disease with the primary symptoms of muscle weakness. Firdapse at a Glance Approved in the European Union Manufactured and commercialized by BioMarin in the European Union Designated as an orphan drug in the United States, the European Union and and Switzerland Regulatory Status In December 2009, Firdapse received marketing approval from the European Commission making it the first approved therapy for the symptomatic treatment of LEMS. Firdapse has been designated an orphan drug in the EU, which grants market exclusivity for ten years. Commercialization Plan Firdapse is commercialized by BioMarin in the European Union. In October 2012, BioMarin out-licensed North American rights of Firdapse to Catalyst Pharmaceutical Partners. For more information on Firdapse development plans in the U.S., please r

Catalyst Pharmaceutical Announces Social Media Presence - WSJ.com Catalyst Pharmaceutical Announces Social Media Presence!!! Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on developing safe and effective approved medicines targeting orphan neuromuscular and neurological diseases, today announced that it has joined the social media conversation with a company blog and Twitter handle, which can be found at CatalystPharmaBlog.com and @CatalystPharma respectively. "We are embracing social media to engage with and better understand the patient communities we intend to serve," said Patrick J. McEnany, Chairman and CEO of Catalyst. "We are developing drugs for patients with rare, orphan diseases, and that means we need to go beyond traditional methods of communications to reach and learn from these patients, their families and their care providers." Catalyst will use these social media channels to foster conversations be

The Myasthenia Gravis Association will be supporting Rare Disease Day 2014 on Friday 28 February as a way of raising awareness of Myasthenia Gravis.  The association’s next support group meeting will take place on Thursday 6 March at Demesne Media Arts Centre, Bowness Road, Middleton, M24 4NU at 7.30pm. The Myasthenia Gravis Association exists to promote the welfare of suffers from Myasthenia Gravis, Lambert- Eaton Myasthenic Syndrome (LEMS) and CMS Congenital Myasthenic Syndrome throughout the United Kingdom and the Republic of Ireland.  Myasthenia Gravis is a neuro-muscular condition that affects approximately 1 in 10,000 people in the UK. Myasthenia Gravis is a condition characterised by fluctuating muscle weakness, which in rare cases may be fatal, particularly if left untreated.  Regional Organiser Sarah Sanders said: “There are over 600 people with Myasthenia Gravis in the North West Region and so many more that we are not currently aware of.”  Myasthenia Gravis, like most rare

Narrower-than-Expected Loss at Catalyst Pharma - March 20, 2014 - Zacks.com